Brings Strong Background in Pharmaceutical Manufacturing Operations and Finance to Help Drive Performance and Productivity Jackie Klecker Named Executive Vice President, Quality and Development Services to Focus on Sustaining Company's Strong Regulatory and Compliance Track Record Personnel Moves Bifurcate Operations and Quality Functions to Align with Company's Growth Strategy and Reflect Natural Evolution of Business CHASKA, Minn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has appointed Thomas Guldager as vice president, operations. An

WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p

CHASKA, Minn., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore" or the "Company"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced the appointment of Brikkelle Thompson as senior vice president of human resources. Ms. Thompson brings nearly 25 years of visionary human resources leadership, global experience, and deep talent management to Lifecore, including 14 years in the medical technology, medical device, and healthcare industries. She will be charged with enhancing the company's performance-driven culture, while further strengthening the Lifecore team by maintaining and securing exceptional talent.

4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

Craig Hallum initiated coverage of Lifecore Biomedical with a rating of Buy and set a new price target of $8.00

Barrington Research downgraded Lifecore Biomedical from Outperform to Mkt Perform

Stephens downgraded Lifecore Biomedical from Overweight to Equal-Weight and set a new price target of $2.00 from $11.00 previously

CHASKA, Minn., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it intends to hold a special meeting of its stockholders (the "Special Meeting") on April 10, 2025 (the "Special Meeting Date"), to consider and vote on a proposal to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of its common stock, par value $0.001 per share ("Common Stock") issuable upon conversion of shares of Lifecore's Series A Convertible Preferred Stock, par value $0.001 per share (the "Convertible Preferred Stock") in an amount in exc

Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 Million in Annual Revenue CHASKA, Minn., Jan. 07, 2025 (GLOBE NEWSWIRE) --  Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has entered into a sales agreement with a non-competitive buyer for the company's previously purchased, but not yet installed, high-speed, multi-purpose 10-head isolator filler. Under the terms of the agreement, the buyer will pay Lifecore an aggregate purchase price of $17 million in exchange for the 10-head filler. Lifecore received $

CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that the company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place January 13-16, 2025, in San Francisco, California. Details regarding Lifecore's participation are as follows: 43rd Annual J.P. Morgan Healthcare ConferenceDetails: Lifecore management, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will participate in 1-on-1 meetingsConference Dates: January 13-16, 2025Location: San Francisco, Califo

-- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 -- -- Signed Multiple Development Agreements with New Customers -- -- Strengthened Balance Sheet with Financing Raising Approximately $24.3 Million, and Favorable Restructuring of Credit Facility with BMO -- Conference Call Today at 4:30pm ET CHASKA, Minn., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced its financial results for the second quarter of fiscal 2025. Highlights from Second Quarter of Fiscal 2025: "The second quarter was a very productive time at Lifecore. Our achievements during

CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it will report financial results for the second quarter of fiscal year 2025 on Thursday, January 2, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore's senior management team will host a webcast to discuss financial results for the quarter and review recent corporate developments. To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore's website at: https://ir.lifecore.com/events-pres

Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial Lifecore to Leverage Differentiated Capabilities and Knowledge in Fill and Finish to Support Nirsum's NIH-Funded NRS-033 Development Program CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has been selected by Nirsum Laboratories, Inc. ("Nirsum") to provide CDMO services focused on supporting Nirsum's clinical development of its lead development candidate, NRS-033. The activities to be conducte

Three-Year Term Extension Combined with Simplification and Reduction of Interest Rates Helps Further Strengthen Company's Balance Sheet and Overall Financial Position Builds Upon Other Recent Strategic Financial Activities, including $24.3 Million PIPE Financing Company Continues to Build Strong Foundation for Execution of Growth Strategy; Highlighted by Strengthened Leadership, Improved Financial Position, Enhanced Capabilities, and Expanded Capacity CHASKA, Minn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it has entered in an agreement wit

CHASKA, Minn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it hosted a virtual investor day prior to market open during which Lifecore's senior management team discussed the company's business and strategy for growth in the future, among other topics. A replay of the event is available via webcast and can be accessed by visiting the Events & Presentations section of Lifecore's investor web page at: https://ir.lifecore.com/events-presentations. About Lifecore Biomedical Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a fully integrated contract deve

CHASKA, Minn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that Paul Josephs, the company's president and chief executive officer, will be a featured speaker in a fireside chat at the upcoming Stephens Annual Investment Conference. The conference is being held November 19-21, 2024, in Nashville, Tennessee. Details regarding Lifecore's participation are as follows: Stephens Annual Investment ConferenceDetails: Mr. Josephs will be a featured speaker in a fireside chat and Lifecore management will participate in 1-on-1 meetingsConference Dates: Novembe

CHASKA, Minn., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that it will host a virtual investor day on Thursday, November 21, 2024, prior to market open. The event will take place from 8:00 – 9:30 a.m. Eastern Time and be available via webcast. During the event, members of Lifecore's senior management team will discuss the company's business and strategy for growth in the future, among other topics. To listen to the live webcast, or access the archived webcast, please visit the Events & Presentations section of Lifecore's investor web page at: https:

SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)

SC 13D/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)